DEA diversion investigators and state medical boards reviewing a pain management practice start with the file, not the prescription pad. The signed treatment agreement, the urine drug screen results, and the prescription drug monitoring program (PDMP) report the prescriber pulled before the last refill are the record that shows a controlled substance was prescribed for a legitimate medical purpose rather than handed out on request. A drug screen result that sits in the chart with no note of what the physician did about it reads to an investigator as exactly the gap the review is looking for.
Why These Records Become Evidence
Treatment agreements, urine drug testing and PDMP checks started as clinical risk-management tools for long-term controlled substance therapy. In a DEA or board review, they do the same work for the investigator that they did for the treating physician: they show that risk was assessed and that the assessment drove a decision. The CDC's 2022 clinical practice guideline for prescribing opioids directs clinicians to review a patient's PDMP history before starting opioid therapy and periodically afterward, and to weigh toxicology testing to confirm a patient is taking the prescribed medication and nothing else beside it. Documentation gaps like these support registration actions, from a DEA order to show cause to, in more severe matters, an immediate suspension order imposed before any hearing is held.
What a Treatment Agreement Must Show
A pain agreement earns the name when it sets out what the patient is agreeing to, not only what the physician expects. California's medical board, in its own published prescribing guidelines, lists these core commitments: the patient's agreement to fill controlled substance prescriptions at a single pharmacy, the patient's consent to periodic drug testing, and notice that the prescriber will review the PDMP based on clinical indications. The agreement also has to describe the physician's own obligations, including coverage for refills when the prescriber is unavailable. A copy given to the patient and a note in the chart recording the date it was reviewed turns the agreement from a form into part of the treatment record.
Documenting a Urine Drug Screen That Conflicts With the Plan
A urine drug screen is a two-step test: an initial immunoassay, followed by confirmatory testing for any substance that screens positive. Confirmatory testing matters because an immunoassay can produce a false positive, and because a prescribed opioid can metabolize into a compound that reads as a different drug on a screening panel. California's medical board guidance states that it is important to document clinical decision-making after an abnormal or unexpected result, and that a patient should not be dismissed from care based solely on an unconfirmed screen. A positive cannabis result gets the same treatment: because state law may treat cannabis as legal, the result alone should not end treatment unless the use conflicts with the agreement's terms. The file needs to show what was tested, what the prescriber discussed with the patient, and why the plan changed or stayed the same.
An unexpected urine drug screen result is not itself the problem when the chart shows what was tested, what was discussed, and why the plan changed or held.
PDMP Checks Complete the Monitoring Record
The PDMP report ties the other two records together, telling the prescriber, and later the investigator, whether the patient has prescriptions from other practitioners that the agreement and the drug screen would not otherwise reveal. A separate Health Law Alliance guide on PDMP obligations and enforcement addresses the enforcement exposure created by PDMP query logs themselves. Inside a pain agreement, the PDMP check has a narrower job: confirmation that it was run, on what date, and what it showed.
Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience.
Why Early Legal Counsel Is Critical
It is critical that prescribers and pharmacies promptly retain experienced healthcare defense counsel upon receiving a DEA subpoena, a board inquiry, or any other investigative request tied to controlled substance prescribing. Early legal intervention can protect the provider's rights, ensure appropriate responses to government requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators on the provider's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the provider to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance's DEA defense team represents physicians, pharmacists and prescribing practices in DEA diversion investigations and state board proceedings built on treatment agreements, drug testing records and PDMP data. Contact us today for a free, confidential consultation.
